Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NovoCure Limited reported revenue of $655M, up 8.3% year over year. Operating margin was -23.5% and net margin -20.8%, on a free-cash-flow margin of -11.5% with capital expenditure at 4.1% of revenue. Every figure is computed directly from NVCR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $655M | -23.5% | -20.8% |
| FY2024 | $605M | -28.2% | -27.9% |
| FY2023 | $509M | -45.7% | -40.6% |
| FY2022 | $538M | -16.6% | -17.2% |
| FY2021 | $535M | -8.3% | -10.9% |
How does NVCR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.